GF

Gordon J. Freeman

DI Dana-Farber Cancer Institute: 87 patents #2 of 1,343Top 1%
Harvard University: 25 patents #38 of 3,600Top 2%
BH Brigham and Women's Hospital: 16 patents #20 of 1,764Top 2%
NA Novartis Ag: 13 patents #212 of 5,128Top 5%
EU Emory University: 11 patents #34 of 1,217Top 3%
GI Genetics Institute: 11 patents #30 of 327Top 10%
CC Children'S Medical Center: 7 patents #73 of 1,211Top 7%
Stanford University: 4 patents #598 of 5,197Top 15%
RE Repligen: 3 patents #23 of 102Top 25%
Pfizer: 2 patents #2,078 of 5,153Top 45%
UP University of Pennsylvania: 2 patents #743 of 2,719Top 30%
BC Beth Israel Deaconess Medical Center: 2 patents #158 of 672Top 25%
TH The Children'S Hospital: 1 patents #11 of 49Top 25%
University of Michigan: 1 patents #1,906 of 4,352Top 45%
UB University Of Maryland, Baltimore: 1 patents #465 of 1,115Top 45%
UF US Air Force: 1 patents #6,190 of 16,312Top 40%
UM University Of Maryland: 1 patents #209 of 857Top 25%
TH The Brigham And Woman'S Hospital: 1 patents #1 of 37Top 3%
📍 Brookline, MA: #11 of 3,196 inventorsTop 1%
🗺 Massachusetts: #324 of 88,656 inventorsTop 1%
Overall (All Time): #17,696 of 4,157,543Top 1%
90
Patents All Time

Issued Patents All Time

Showing 1–25 of 90 patents

Patent #TitleCo-InventorsDate
12258409 Method of assessing the efficacy of a test agent for modulating programmed death 1 (PD-1) signaling by using anti-phosphotyrosinylated PD-1 monoclonal antibodies Vassiliki Boussiotis, Xia Bu, Vikram Juneja, Arlene H. Sharpe, Nikolaos Patsoukis +2 more 2025-03-25
12186278 Mesothelin chimeric antigen receptor (CAR) and antibody against PD-L1 inhibitor for combined use in anticancer therapy Jennifer Brogdon, Hwai Wen Chang, Boris Engels, Gerhard Frey, Jennifer Marie Mataraza +2 more 2025-01-07
12139535 Methods for upregulating immune responses using combinations of anti-RGMb and anti-PD-1 agents Yanping Xiao 2024-11-12
12103972 KIR3DL3 as an HHLA2 receptor, anti-HHLA2 antibodies, and uses thereof Antonio Arulanandam 2024-10-01
11827704 Antibody molecules to PD-1 and uses thereof Arlene H. Sharpe, Walter A. Blattler, Jennifer Marie Mataraza, Catherine Anne Sabatos-Peyton, Hwai Wen Chang +1 more 2023-11-28
11584788 Compositions and methods for identification, assessment, prevention, and treatment of melanoma using PD-L1 isoforms F. Stephen Hodi, Jun Zhou, Jingjing Li, Xinqi Wu 2023-02-21
11492403 Anti-phosphotyrosinylated programmed death 1 (PD-1) monoclonal antibodies, methods of making and methods of using thereof Vassiliki Boussiotis, Xia Bu, Vikram Juneja, Arlene H. Sharpe, Nikolaos Patsoukis +2 more 2022-11-08
11485787 Agents that modulate RGMb-neogenin-BMP signaling and methods of use thereof Rosemarie Dekruyff, Dale T. Umetsu, Sanhong Yu, Yanping Xiao 2022-11-01
11413340 Mesothelin chimeric antigen receptor (CAR) and antibody against PD-L1 inhibitor for combined use in anticancer therapy Jennifer Brogdon, Hwai Wen Chang, Boris Engels, Gerhard Frey, Jennifer Marie Mataraza +2 more 2022-08-16
11359013 Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (PD-1) pathway Arlene H. Sharpe, David M. Dorfman, Rafi Ahmed, Daniel Barber, E. John Wherry 2022-06-14
11359020 Agents that modulate immune cell activation and methods of use thereof Arlene H. Sharpe, Yanping Xiao, Loise M. Francisco, Rosemarie Dekruyff, Dale T. Umetsu 2022-06-14
11261251 Human anti-PD-1, PD-L1, and PD-L2 antibodies and uses therefor Rafi Ahmed, Timothy David Jones, Francis Joseph Carr, James P. Gregson 2022-03-01
11220545 Methods for upregulating immune responses using combinations of anti-RGMb and anti-PD-1 agents Yanping Xiao 2022-01-11
11207393 Regulatory T cell PD-1 modulation for regulating T cell effector immune responses Arlene H. Sharpe, Loise M. Francisco, Peter T. Sage, Sun-Jong Lee, Scott B. Lovitch +2 more 2021-12-28
11155620 Method of detecting TIM-3 using antibody molecules to TIM-3 Catherine Anne Sabatos-Peyton, Barbara Brannetti, Alan S. Harris, Thomas Huber, Thomas Pietzonka +9 more 2021-10-26
11124569 Methods of reducing liver PD-1-expressing CD8+ T cells using PD-1 Fc fusion proteins that bind Fc receptors Rafi Ahmed, Arlene H. Sharpe, Masao Hashimoto, Hyun T. Jin 2021-09-21
11116818 Compositions and methods for inhibiting viral entry Hyeryun Choe, Stephanie Jemielity, Dale T. Umetsu, Rosemarie H. De Kruyff 2021-09-14
10981990 Antibody molecules to TIM-3 and uses thereof Catherine Anne Sabatos-Peyton, Barbara Brannetti, Alan S. Harris, Thomas Huber, Thomas Pietzonka +9 more 2021-04-20
10960008 Methods for treating PTEN deficient epithelial cancers using a combination of anti-PI3KBETA and anti-immune checkpoint agents Jean Zhao, Johann Bergholz, Thomas M. Roberts 2021-03-30
10948492 PD-L2 biomarkers predictive of PD-1 pathway inhibitor responses in esophagogastric cancers Adam Bass, Sarah Derks, Scott J. Rodig 2021-03-16
10934353 Single agent anti-PD-L1 and PD-L2 dual binding antibodies and methods of use Arlene H. Sharpe 2021-03-02
10865233 NKG2D-fc for immunotherapy Glenn Dranoff, Matthew Vanneman 2020-12-15
10851165 Antibody molecules to PD-L1 and methods of treating cancer Arlene H. Sharpe, Gerhard Frey, Hwai Wen Chang, Jennifer Marie Mataraza, Glenn Dranoff 2020-12-01
10752687 Antibody molecules to PD-1 and uses thereof Arlene H. Sharpe, Walter A. Blattler, Jennifer Marie Mataraza, Catherine Anne Sabatos-Peyton, Hwai Wen Chang +1 more 2020-08-25
10472419 Antibody molecules to TIM-3 and uses thereof Catherine Anne Sabatos-Peyton, Barbara Brannetti, Alan S. Harris, Thomas Huber, Thomas Pietzonka +9 more 2019-11-12